【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 2567次   下载 312  
盐酸尼卡地平缓释微丸的药代动力学及生物利用度
孙其荣,张国庆,钟延强,刘善奎
0
()
摘要:
目的:比较自制的盐酸尼卡地平缓释微丸(NIC-SP)与普通市售盐酸尼卡地平片剂、进口缓释尼卡地平胶囊(Perdipine LA)的药代动力学及生物利用度。方法:采用拉丁方试验设计,将志愿者6人随机分为3组,交叉口服NIC-SP、普通市售片剂和Perdipine LA,以普通片剂和Perdipine LA为对照制剂,计算NIC-SP的相对生物利用度。结果:NIC-SP相对于Perdipine LA的生物利用度为116.09%;两种制剂的AUC及体内平均驻留时间(MRT)有显著性差异(P<0.05);达峰时间,峰浓度,消除速率常数和吸收速率常数均没有显著性差异(P>0.05)。NIC-SP和Perdipine LA相对于普通片剂的生物利用度分别为86.53%和74.54%。结论:NIC-SP体内缓释效果优于进口的Perdipine LA,达到设计要求。
关键词:  盐酸尼卡地平  迟效制剂  药代动力学  生物利用度
DOI:
基金项目:
Study on pharmacokinetics and bioavailability of nicardipine hydrochloride sustained-release pellets
孙其荣,张国庆,钟延强,刘善奎
()
Abstract:
Objective: To compare the pharmacokinetics and bioavailability of nicardipine hydrochloride sustained-release pellets (NIC-SP) with common market tablets and imported sustained-release capsules (Perdipine LA). Methods: Latin test was employed in the single oral administration of NIC-SP, common market tablets and Perdipine LA with 6 volunteers. The relative bioavailabilities of NIC-SP against market tablet and Perdipine LA were calculated. Results: The bioavailability of NIC-SP against Perdipine LA is 116.09%. The bioavailabilities of NIC-SP and Perdipine LA against market tablet is 86.53%and 74.54%, respectively. There were significant differences between AUC, MRT of NIC-SP and Perdipine LA (P<0.05), while tmax,cmax,ke and ka of them did not show significant difference(P>0.05). Conclusion: The sustained effect of NIC-SP is better than the Perdipine LA in vivo.
Key words:  nicardipine hydrochloride  sustained-release pellets  pharmacokinetics  bioavailability